[HTML][HTML] Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

A Rodriguez-Meira, R Norfo, S Wen, AL Chédeville… - Nature …, 2023 - nature.com
Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …

[HTML][HTML] Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms

E Grockowiak, C Korn, J Rak, V Lysenko, A Hallou… - Nature Cancer, 2023 - nature.com
Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal
hematopoiesis-related somatic mutations and the development of myeloid malignancies …

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges

HO Ajufo, JA Waksal… - Therapeutic …, 2023 - journals.sagepub.com
Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies that
include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) …

[HTML][HTML] Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases

E La Spina, S Giallongo, C Giallongo, N Vicario… - Frontiers in …, 2023 - frontiersin.org
Chronic myeloproliferative neoplasms encompass the BCR-ABL1-negative neoplasms
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) …

Inflammation drives pressure on TP53 mutant clones in myeloproliferative neoplasms

A Benabid, RK Schneider - Nature Genetics, 2023 - nature.com
Transformation of a myeloproliferative neoplasm to a secondary acute myeloid leukemia is
rare but devastating. Single-cell, multi-omic characterization of hematopoietic stem and …

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes

M Rafati, DW Brown, W Zhou, K Jones, W Luo… - Blood …, 2023 - ashpublications.org
Abstract JAK2 V617F is the most common driver mutation in primary or secondary
myelofibrosis for which allogeneic hematopoietic cell transplantation (HCT) is the only …

[HTML][HTML] Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm

DH Kim, JM Byun, DY Shin, I Kim, SS Yoon… - Blood …, 2023 - synapse.koreamed.org
STUDY DESIGN This was an investigator-initiated phase II open-label single-arm study.
Adult (age≥ 18 yr) patients with cytologically confirmed AML following MPN were eligible if …

Patient-specific comorbidities as prognostic variables for survival in myelofibrosis

AL Sochacki, CA Bejan, S Zhao, A Patel… - Blood …, 2023 - ashpublications.org
Abstract Treatment decisions in primary myelofibrosis (PMF) are guided by numerous
prognostic systems. Patient-specific comorbidities have influence on treatment-related …

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?

D Mahdi, J Spiers, A Rampotas… - British Journal of …, 2023 - Wiley Online Library
Management approaches for accelerated and blast phase myeloproliferative neoplasms
remain challenging for clinicians and patients alike. Despite many therapeutic advances …

[HTML][HTML] Ph 染色体阴性骨髓增殖性肿瘤加速/急变期患者的临床特征及预后因素分析

严欣, 秦铁军, 李冰, 曲士强, 潘丽娟… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
Ph染色体阴性骨髓增殖性肿瘤加速/急变期患者的临床特征及预后因素分析- PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …